Eli Lilly and Co
LLY1077.520USD
+0.540+0.05%
종가 12/26, 16:00（ET）시세는 15분 지연됩니다
1.02T시가총액
52.57P/E TTM
자세한 내용은 Eli Lilly and Co 회사
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).
Eli Lilly and Co 정보
종목 코드 LLY
회사 이름Eli Lilly and Co
상장일Jul 09, 1970
CEORicks (David A)
직원 수47000
유형Ordinary Share
회계 연도 종료Jul 09
주소Lilly Corporate Ctr
도시INDIANAPOLIS
증권 거래소NASDAQ OMX NASDAQ Basic NYSE
국가United States of America
우편 번호46285
전화13172762000
웹사이트https://www.lilly.com/
종목 코드 LLY
상장일Jul 09, 1970
CEORicks (David A)
Eli Lilly and Co의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.57K
+0.30%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.73K
-0.04%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
26.26K
-4.54%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
25.66K
-41.06%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.37K
+0.93%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
19.72K
+77.63%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
14.69K
+5.12%
Mr. Eric Dozier
Mr. Eric Dozier
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
9.84K
+15.72%
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.57K
+0.30%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.73K
-0.04%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
26.26K
-4.54%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
25.66K
-41.06%
수익 분석
통화: USD마지막 업데이트: Mon, Oct 6
통화: USD마지막 업데이트: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
Diabetes-Mounjaro
5.20B
33.42%
Diabetes-Zepbound
3.38B
21.73%
Oncology-Verzenio
1.49B
9.57%
Diabetes-Trulicity
1.09B
7.02%
Diabetes-Other Diabetes
980.40M
6.30%
기타
3.42B
21.95%
지역별USD
이름
수익
비율
U.S.
10.81B
69.51%
Europe
2.57B
16.55%
Other foreign countries
1.18B
7.60%
Japan
521.00M
3.35%
China
465.90M
2.99%
사업별
지역별
사업별USD
이름
수익
비율
Diabetes-Mounjaro
5.20B
33.42%
Diabetes-Zepbound
3.38B
21.73%
Oncology-Verzenio
1.49B
9.57%
Diabetes-Trulicity
1.09B
7.02%
Diabetes-Other Diabetes
980.40M
6.30%
기타
3.42B
21.95%
주식 보유 통계
마지막 업데이트: Wed, Nov 12
마지막 업데이트: Wed, Nov 12
주주
주주 유형
주주
주주
비율
Lilly Endowment, Inc.
9.75%
The Vanguard Group, Inc.
8.52%
PNC Investments LLC
5.41%
BlackRock Institutional Trust Company, N.A.
4.43%
State Street Investment Management (US)
3.67%
기타
68.21%
주주
주주
비율
Lilly Endowment, Inc.
9.75%
The Vanguard Group, Inc.
8.52%
PNC Investments LLC
5.41%
BlackRock Institutional Trust Company, N.A.
4.43%
State Street Investment Management (US)
3.67%
기타
68.21%
주주 유형
주주
비율
Investment Advisor
45.38%
Investment Advisor/Hedge Fund
18.69%
Foundation
9.75%
Research Firm
2.04%
Pension Fund
1.89%
Bank and Trust
1.84%
Insurance Company
1.48%
Sovereign Wealth Fund
1.29%
Hedge Fund
0.74%
기타
16.90%
기관 주식 보유
마지막 업데이트: Wed, Oct 1
마지막 업데이트: Wed, Oct 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q3
5762
789.85M
83.53%
-6.48M
2025Q2
5717
798.76M
84.28%
+2.87M
2025Q1
5710
800.38M
84.44%
+5.04M
2024Q4
5528
795.43M
83.87%
+627.51K
2024Q3
5177
793.57M
83.49%
-5.03M
2024Q2
5068
795.80M
83.72%
-2.01M
2024Q1
4916
795.04M
83.62%
-6.22M
2023Q4
4670
799.46M
84.21%
-2.37M
2023Q3
4354
800.21M
84.30%
-1.19M
2023Q2
4197
799.48M
84.22%
-4.32M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Lilly Endowment, Inc.
95.49M
10.09%
-243.99K
-0.25%
Sep 30, 2025
The Vanguard Group, Inc.
80.05M
8.46%
+1.17M
+1.49%
Jun 30, 2025
PNC Investments LLC
51.08M
5.4%
-9.49K
-0.02%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
41.30M
4.36%
-168.44K
-0.41%
Jun 30, 2025
State Street Investment Management (US)
34.51M
3.65%
+69.02K
+0.20%
Jun 30, 2025
Capital Research Global Investors
20.76M
2.19%
+5.01M
+31.81%
Jun 30, 2025
Fidelity Management & Research Company LLC
24.36M
2.57%
-2.82M
-10.39%
Jun 30, 2025
Geode Capital Management, L.L.C.
18.13M
1.92%
-397.62K
-2.15%
Jun 30, 2025
Capital World Investors
17.63M
1.86%
-748.08K
-4.07%
Jun 30, 2025
Wellington Management Company, LLP
13.99M
1.48%
+1.28M
+10.09%
Jun 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
VanEck Pharmaceutical ETF
47.56%
iShares U.S. Pharmaceuticals ETF
25.23%
Harbor Health Care ETF
18.24%
Roundhill GLP-1 & Weight Loss ETF
16.7%
Health Care Select Sector SPDR Fund
14.06%
Proshares Ultra Health Care
13.57%
iShares U.S. Healthcare ETF
13.54%
Amplify Weight Loss Drug & Treatment ETF
11.93%
Fidelity MSCI Health Care Index ETF
11.73%
Goldman Sachs Future Health Care Equity ETF
10.84%
더 보기
VanEck Pharmaceutical ETF
비율47.56%
iShares U.S. Pharmaceuticals ETF
비율25.23%
Harbor Health Care ETF
비율18.24%
Roundhill GLP-1 & Weight Loss ETF
비율16.7%
Health Care Select Sector SPDR Fund
비율14.06%
Proshares Ultra Health Care
비율13.57%
iShares U.S. Healthcare ETF
비율13.54%
Amplify Weight Loss Drug & Treatment ETF
비율11.93%
Fidelity MSCI Health Care Index ETF
비율11.73%
Goldman Sachs Future Health Care Equity ETF
비율10.84%
주식 배당금
지난 5년 동안 총
18.06B
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
Oct 27, 2025
LLY.NB Final Cash Dividend of gross USD 1.5 paid on Dec 10, 2025 going ex on Nov 14, 2025
Nov 14, 2025
Dec 10, 2025
Nov 14, 2025
Jun 23, 2025
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Sep 10, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Sep 10, 2025
Aug 15, 2025
May 05, 2025
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Jun 10, 2025 going ex on May 16, 2025
May 16, 2025
Jun 10, 2025
May 16, 2025
Dec 09, 2024
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 10, 2025
Feb 14, 2025
Oct 28, 2024
LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024
Nov 15, 2024
Dec 10, 2024
Nov 15, 2024
Jun 24, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024
Aug 15, 2024
Sep 10, 2024
Aug 15, 2024
May 06, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024
May 16, 2024
Jun 10, 2024
May 15, 2024
Dec 08, 2023
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024
Feb 15, 2024
Mar 08, 2024
Feb 14, 2024
Nov 01, 2023
LLY.NB Final Cash Dividend of gross USD 1.13 paid on Dec 08, 2023 going ex on Nov 14, 2023
Nov 15, 2023
Dec 08, 2023
Nov 14, 2023
Jun 26, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Sep 08, 2023 going ex on Aug 14, 2023
Aug 15, 2023
Sep 08, 2023
Aug 14, 2023
더 보기
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
자주 묻는 질문
Eli Lilly and Co의 상위 5대 주주는 누구인가요?
Eli Lilly and Co의 상위 5대 주주는 다음과 같습니다:
Lilly Endowment, Inc.는 95.49M주의 주식을 보유하고 있으며, 전체 주식의 10.09%를 차지합니다.
The Vanguard Group, Inc.는 80.05M주의 주식을 보유하고 있으며, 전체 주식의 8.46%를 차지합니다.
PNC Investments LLC는 51.08M주의 주식을 보유하고 있으며, 전체 주식의 5.40%를 차지합니다.
BlackRock Institutional Trust Company, N.A.는 41.30M주의 주식을 보유하고 있으며, 전체 주식의 4.36%를 차지합니다.
State Street Investment Management (US)는 34.51M주의 주식을 보유하고 있으며, 전체 주식의 3.65%를 차지합니다.
Lilly Endowment, Inc.는 95.49M주의 주식을 보유하고 있으며, 전체 주식의 10.09%를 차지합니다.
The Vanguard Group, Inc.는 80.05M주의 주식을 보유하고 있으며, 전체 주식의 8.46%를 차지합니다.
PNC Investments LLC는 51.08M주의 주식을 보유하고 있으며, 전체 주식의 5.40%를 차지합니다.
BlackRock Institutional Trust Company, N.A.는 41.30M주의 주식을 보유하고 있으며, 전체 주식의 4.36%를 차지합니다.
State Street Investment Management (US)는 34.51M주의 주식을 보유하고 있으며, 전체 주식의 3.65%를 차지합니다.
Eli Lilly and Co의 상위 3대 주주 유형은 무엇인가요?
Eli Lilly and Co의 주요 주주 유형 상위 3가지는
Lilly Endowment, Inc.
The Vanguard Group, Inc.
PNC Investments LLC입니다.
Lilly Endowment, Inc.
The Vanguard Group, Inc.
PNC Investments LLC입니다.
Eli Lilly and Co(LLY)의 주식을 보유한 기관은 몇 개입니까?
2025Q3 기준으로, Eli Lilly and Co의 주식을 보유한 기관은 총 5762곳이며, 이들이 보유한 주식의 총 가치는 약 789.85M로 전체 발행 주식의 83.53%를 차지합니다. 이는 2025Q2 대비 -0.75% 증가한 수치입니다.
Eli Lilly and Co의 최대 수익원은 무엇인가요?
FY2025Q2 기준, Eli Lilly and Co의 Diabetes-Mounjaro 부문이 가장 높은 매출을 기록했으며, 금액은 5.20B로 전체 매출의 33.42%를 차지했습니다.
